fda warning letters compounded semaglutide 2024 2025 issued 25 to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of The Food and Drug Administration

This collective pressure has culminated in a significant strain on supplies of semaglutide-based drugs, affecting both the diabetic and non-diabetic populace who depend on these treatments

Clinical studies consistently show that most people who stop semaglutide or tirzepatide regain a substantial portion of the weight they lost and research suggests the regained weight is disproportionately fat rather than the lean muscle mass that may have been lost during treatment

The clinical result is a medication that works through three complementary pathways simultaneously: Reduced appetite via GLP-1 and GIP receptor activation (eating less) Improved metabolic efficiency via GIP receptor activation on adipose tissue (storing fat less efficiently) Increased energy expenditure via glucagon receptor activation (burning more calories) This triple mechanism explains why retatrutides Phase 3 trial results exceed Mounjaros, which already uses two pathways

Starting July 1, 2026, the Centers for Medicare and Medicaid Services launches the Medicare GLP-1 Bridge, a demonstration program that lets eligible Medicare Part D members get certain weight-loss drugs for a flat $50 monthly copay through December 31, 2027

Baden, L

Mix it with water if you prefer a milder taste